New Delhi: With data and studies about the Kovid-19 vaccine covaxin Presented to the Director of World Health Organisation, All India Institute of Medical Sciences (AIIMS) Delhi Randeep Guleria The vaccine is expected to be granted authorization for an emergency use list soon.
speaking on the issue Guleria “We are hopeful that now that all the data and studies have been done, it should be sooner rather than late,” he told ANI.
“It will make travel easier; it will encourage people, especially those who have taken both shots of the vaccine, to be able to travel abroad. Also approval as we start to come out of the pandemic.” It is very important to have so that one does not need to be quarantined or isolated at any place,” added Dr Guleria.
He further appealed to be alert and vigilant for the next 6-8 weeks, only then we will be able to see a decline in the total number of COVID-19 cases.
Although individual European countries have recognized the Serum Institute of India (SII) Covishield, to date the European Union (EU) which has introduced the EU Digital Covid Certificate (EUDCC) has yet to process visas for India. Not approved.
In a relaxed approach, the UK changed its visa status to India with an “amber” category.
The WHO has followed four phases for the approval process for the COVID vaccine which includes acceptance of the Expression of Interest (EoI) of the manufacturer, a pre-submission meeting between WHO and the manufacturer, and the status of the dossier for evaluation by WHO. decision is involved. Why assessment?
Bharat Biotech’s dossier is being reviewed since July.
Former Union Health Minister Mansukh Mandaviya Met with the WHO chief scientist to discuss the approval of Covaxin.
Bharat Biotech had earlier tweeted, “Covaxin clinical trial data was fully compiled and available in June 2021. All data submitted for Emergency Use List (EUL) application to the World Health Organization in early July We have responded to any clarifications sought by WHO and are awaiting further response.”
The WHO has so far approved COVID vaccines for emergency use developed by Pfizer-BioNtech, US pharma major Johnson & Johnson, Moderna, China’s Sinopharm and Oxford-AstraZeneca.
speaking on the issue Guleria “We are hopeful that now that all the data and studies have been done, it should be sooner rather than late,” he told ANI.
“It will make travel easier; it will encourage people, especially those who have taken both shots of the vaccine, to be able to travel abroad. Also approval as we start to come out of the pandemic.” It is very important to have so that one does not need to be quarantined or isolated at any place,” added Dr Guleria.
He further appealed to be alert and vigilant for the next 6-8 weeks, only then we will be able to see a decline in the total number of COVID-19 cases.
Although individual European countries have recognized the Serum Institute of India (SII) Covishield, to date the European Union (EU) which has introduced the EU Digital Covid Certificate (EUDCC) has yet to process visas for India. Not approved.
In a relaxed approach, the UK changed its visa status to India with an “amber” category.
The WHO has followed four phases for the approval process for the COVID vaccine which includes acceptance of the Expression of Interest (EoI) of the manufacturer, a pre-submission meeting between WHO and the manufacturer, and the status of the dossier for evaluation by WHO. decision is involved. Why assessment?
Bharat Biotech’s dossier is being reviewed since July.
Former Union Health Minister Mansukh Mandaviya Met with the WHO chief scientist to discuss the approval of Covaxin.
Bharat Biotech had earlier tweeted, “Covaxin clinical trial data was fully compiled and available in June 2021. All data submitted for Emergency Use List (EUL) application to the World Health Organization in early July We have responded to any clarifications sought by WHO and are awaiting further response.”
The WHO has so far approved COVID vaccines for emergency use developed by Pfizer-BioNtech, US pharma major Johnson & Johnson, Moderna, China’s Sinopharm and Oxford-AstraZeneca.
.